Novo Nordisk's obesity therapy Wegovy put in another strong sales performance ... pharmaceutical ingredients and finished injectable products – that will result in "continued periodic supply ...

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's expectations and bumping its stock up more than 4% at market open.

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face ...

Novo Nordisk has such a blockbuster with Wegovy and Ozempic ... Novo Nordisk also manufactures and markets pharmaceutical products related to hormone therapy, hemophilia and growth disorders.

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

with key products like Ozempic and Wegovy patent-protected until 2031-2032. Despite high CapEx impacting free cash flow, future guidance suggests significant growth, making Novo Nordisk a cautious ...

And the deal will result in a hit of $1.26 billion this year from debt financing. Injection pens and boxes of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, ...